Novartis Ag (NVSEF) Gross Margin Growth (3y) (2013 - 2025)
Novartis Ag (NVSEF) Gross Margin Growth (3y) (2013 - 2025) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Gross Margin Growth (3y) (Qtr) |
| 1 |
Gsk |
92,316,836.42 Bn |
92,316,831.46 Bn |
7.76 Bn |
338.00 |
| 2 |
Eli Lilly |
983.57 Bn |
978.29 Bn |
16.22 Bn |
531.00 |
| 3 |
Johnson & Johnson |
553.56 Bn |
531.50 Bn |
15.96 Bn |
-168.00 |
| 4 |
AbbVie |
383.35 Bn |
374.00 Bn |
10.78 Bn |
449.00 |
| 5 |
Merck |
281.71 Bn |
276.06 Bn |
12.09 Bn |
134.00 |
| 6 |
Amgen |
182.20 Bn |
170.16 Bn |
5.87 Bn |
-367.00 |
| 7 |
Gilead Sciences |
153.71 Bn |
145.98 Bn |
5.52 Bn |
129.00 |
| 8 |
Pfizer |
143.75 Bn |
130.98 Bn |
-1.21 Bn |
-1,698.00 |
| 9 |
Bristol Myers Squibb |
109.71 Bn |
99.25 Bn |
8.07 Bn |
-714.00 |
| 10 |
Novartis Ag |
- |
- |
- |
- |
| Date | Value |
|---|
| Jun 30, 2025 |
890.00 |
| Dec 31, 2024 |
7,686.00 |
| Jun 30, 2024 |
7,752.00 |
| Dec 31, 2023 |
6,287.00 |
| Jun 30, 2023 |
127.00 |
| Mar 31, 2023 |
154.31 Mn |
| Jun 30, 2022 |
-23.00 |
| Mar 31, 2022 |
429.00 |
| Dec 31, 2021 |
-38,547.00 |
| Sep 30, 2021 |
-20,600.00 |
| Jun 30, 2021 |
-6,821.00 |
| Mar 31, 2021 |
-256.00 |
| Dec 31, 2020 |
-39,478.00 |
| Sep 30, 2020 |
756.26 Mn |
| Jun 30, 2020 |
493.00 |
| Jun 30, 2019 |
-38,146.00 |
| Mar 31, 2019 |
894.00 |
| Dec 31, 2018 |
-111,140.00 |
| Sep 30, 2018 |
-28,195.00 |
| Jun 30, 2018 |
-38,242.00 |
